JPRN-UMIN000003737已完成未知
Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer with EGFR Mutation (CJLSG0910) - Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer with EGFR Mutation
Central Japan Lung Study Group0 个研究点目标入组 32 人开始时间: 2010年6月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Brain metastasis 2) Hemoptysis (>=2.5ml) 3) Active infection 4) Fever 5) Serious disease condition 6) Active double cancer 7) Cavity fluid retention difficult to control 8) Severe drug allergy 9) Receiving anticoagulant drug (except Aspirin under 325mg/day) 10) Active GI bleeding or inflammation in the abdominal cavity. 11) Pregnancy or lactation 12) Patients whose participation in the trial is judged to be inappropriate by the attending doctor
研究者
相似试验
已完成
2 期
Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer without EGFR Mutation (CJLSG0909)Advanced non-squamous non-small cell lung cancer without EGFR MutationJPRN-UMIN000003736Central Japan Lung Study Group52
已完成
2 期
Phase II Study of Carboplatin+Pemetrexed+Bevacizumab in chemo-naive patients with stage IIIB and IV non-squamous non-small cell lung cancer(NSCLC).non-squamous non-small cell lung cancerJPRN-UMIN000003387Kansai Medical University Hirakata Hospital25
已完成
2 期
Phase II study of Pemetrexed and Carboplatin plus Bevacizumab for advanced non-small cell lung cancernon-squamous non-small-cell lung cancerJPRN-UMIN000003680ippon Medical School Hospital26
招募中
2 期
A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancer (EGFR mutation status Negative)JPRN-UMIN000005991Toho University Omori Medical Center35
已完成
2 期
A Phase II study of Pemetrexed plus Carboplatin Plus Bevacizumab followed by maintenance Pemetrexed Plus Bevacizumab in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer.on-squamous non-small cell lung cancerJPRN-UMIN000003770Osaka Lung Cancer Study Group40